ASH 2022 | Phase I study of forimtamig, a GPRC5DxCD3 bispecific antibody, in R/R multiple myeloma
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, comments on Phase I dose escalation results for forimtamig (formerly RG6234; NCT04557150), a bispecific T-cell engager that binds CD3+ T-cells and GPRC5D on myeloma plasma cells. Overall, the antibody was observed to have a very high overall response rate, with a number of patients achieving very good partial and complete responses. Forimtamig did induce cytokine release syndrome (CRS), as well as skin and mucosal toxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AstraZeneca: Honoraria; Sanofi: Other: Consultancy/Advisory, Research Funding; Bristol Myers Squibb: Honoraria; Merck Sharp & Dohme: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Incyte: Honoraria; Janssen Oncology: Honoraria; Celgene/Bristol Myers Squibb: Other: Consultancy/Advisory; Roche: Other: Consultancy/Advisory, Research Funding; ADC Therapeutics: Honoraria, Other: Consultancy/Advisory, Research Funding; Karyopharm Therapeutics: Other: Consultancy/Advisory; Scenic Biotech: Other: Consultancy/Advisory.
